Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase NA 1Phase 4 1

Status

Recruiting 4Not yet recruiting 3

Sponsor Class

OTHER 6OTHER_GOV 1

Study Type

Interventional 6Observational 1

Sponsor

Cancer Type

Breast 5Thoracic 1Head & Neck 1

Conditions

Breast Neoplasms 4Salivary Gland Neoplasms 1Lung Neoplasms 1HER2-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Specimen Handling 641pembrolizumab 585Magnetic Resonance Spectroscopy 555Carboplatin 431Cyclophosphamide 381Cisplatin 379Biopsy 376Nivolumab 315Paclitaxel 314Gemcitabine 308Radiotherapy 286Bevacizumab 235Dexamethasone 218fludarabine 206Docetaxel 194durvalumab 189Oxaliplatin 189venetoclax 187Rituximab 175Fluorouracil 175atezolizumab 172Pemetrexed 167Capecitabine 164Radiosurgery 162Doxorubicin 162Radiation 160Ipilimumab 146Lenalidomide 140Leucovorin 138Etoposide 134

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
pyrotinib × 90 days × Clear all
NCT07600164 2026-05-20

Real-world Study of Pyrotinib-containing Regimens of Advanced HER2-positive Breast Cancer

Peking University People's Hospital

Phase 4 Not yet recruiting
500 enrolled
Breast

Breast Neoplasms

NCT06563999 2026-04-21

NUMER

Sun Yat-sen University

Phase 2 Recruiting
120 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06145308 2026-04-02

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Peking Union Medical College

Phase 2 Recruiting
39 enrolled
Head & Neck

Salivary Gland Neoplasms

NCT05769010 2026-04-01

Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases

Henan Cancer Hospital

Phase 2 Recruiting
150 enrolled
Breast

Breast Neoplasms

NCT07335081 2026-03-24

ctDNA in HER2+ EBC Neoadjuvant Treatment

Shanghai Jiao Tong University School of Medicine

Phase 2 Recruiting
60 enrolled
Breast

Breast Neoplasms

NCT06495541 2026-03-20

The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 Positive

Tianjin Medical University Cancer Institute and Hospital

Phase NA Not yet recruiting
500 enrolled
Breast

Breast Neoplasms

NCT07470203 2026-03-13

Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer

Peking University Cancer Hospital & Institute

Not yet recruiting
42 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡